

Cynthia A Lemere

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3824305/cynthia-a-lemere-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

63
papers

10,096
citations

32
h-index

79
g-index

79
ext. papers

12,030
ext. citations

10.1
avg, IF

5.85
L-index

#	Paper	IF	Citations
63	Microbiota in neuroinflammation and synaptic dysfunction: a focus on Alzheimer's disease.. <i>Molecular Neurodegeneration</i> , 2022 , 17, 19	19	5
62	Aducanumab produced a clinically meaningful benefit in association with amyloid lowering. <i>Alzheimer's Research and Therapy</i> , 2021 , 13, 98	9	57
61	APOE ϵ Association With Cognition and Alzheimer Disease Biomarkers in Down Syndrome-Implications for Clinical Trials and Treatments for All. <i>JAMA Neurology</i> , 2021 , 78, 913-915	17.2	0
60	Focused ultrasound with anti-pGlu3 A β enhances efficacy in Alzheimer's disease-like mice via recruitment of peripheral immune cells. <i>Journal of Controlled Release</i> , 2021 , 336, 443-456	11.7	4
59	Global C3 lowering alleviates hippocampal dysfunction and cognitive impairment in aged mice.. <i>Alzheimer's and Dementia</i> , 2021 , 17 Suppl 2, e058736	1.2	
58	Focus Ultrasound-Induced Blood-Brain Barrier opening enhances anti-pGlu3 A β nAb delivery and amyloid-beta plaque clearance.. <i>Alzheimer's and Dementia</i> , 2021 , 17 Suppl 2, e058725	1.2	
57	Vaccination against the broadly expressed microbial antigen PNAG prevents cognitive decline in the APP-PS1 mouse model of Alzheimer's disease.. <i>Alzheimer's and Dementia</i> , 2021 , 17 Suppl 3, e053793 ^{1.2}	1.2	
56	Global complement C3 lowering in adult mice protects hippocampal synaptic function.. <i>Alzheimer's and Dementia</i> , 2021 , 17 Suppl 3, e057867	1.2	
55	A novel inducible complement C3 conditional knockout mouse model: Generation and characterization. <i>Alzheimer's and Dementia</i> , 2020 , 16, e047192	1.2	
54	Development of the clinical candidate PBD-C06, a humanized pGlu3-A β specific antibody against Alzheimer's disease with reduced complement activation. <i>Scientific Reports</i> , 2020 , 10, 3294	4.9	8
53	Effector function of anti-pyroglutamate-3 A β antibodies affects cognitive benefit, glial activation and amyloid clearance in Alzheimer's-like mice. <i>Alzheimer's Research and Therapy</i> , 2020 , 12, 12	9	15
52	Microglia Do Not Take Up Soluble Amyloid-beta Peptides, But Partially Degrade Them by Secreting Insulin-degrading Enzyme. <i>Neuroscience</i> , 2020 , 443, 30-43	3.9	6
51	Phosphorylated A β peptides in human Down syndrome brain and different Alzheimer's-like mouse models. <i>Acta Neuropathologica Communications</i> , 2020 , 8, 118	7.3	7
50	Space-like Fe irradiation manifests mild, early sex-specific behavioral and neuropathological changes in wildtype and Alzheimer's-like transgenic mice. <i>Scientific Reports</i> , 2019 , 9, 12118	4.9	23
49	Active Amyloid- β Vaccination Results in Epigenetic Changes in the Hippocampus of an Alzheimer's Disease-Like Mouse Model. <i>Current Alzheimer Research</i> , 2019 , 16, 861-870	3	4
48	BrightFocus Alzheimer's Fast Track 2019. <i>Molecular Neurodegeneration</i> , 2019 , 14, 48	19	
47	Paving the Way for Therapy: The Second International Conference of the Trisomy 21 Research Society. <i>Molecular Syndromology</i> , 2019 , 9, 279-286	1.5	6

46	Age-related epigenetic changes in hippocampal subregions of four animal models of Alzheimer's disease. <i>Molecular and Cellular Neurosciences</i> , 2018 , 86, 1-15	4.8	26
45	P1-099: COMBINATION OF A GLUTAMINYL CYCLASE INHIBITOR (PQ912) AND A PYROGLUTAMATE-A β SPECIFIC ANTIBODY (PBD-M06) SHOWS ADDITIVE EFFECTS IN A MOUSE MODEL WITH ALZHEIMER'S DISEASE-LIKE PATHOLOGY 2018 , 14, P309-P309		
44	Traumatic Brain Injury in Aged Mice Induces Chronic Microglia Activation, Synapse Loss, and Complement-Dependent Memory Deficits. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	59
43	Passive A β immunotherapy: Current Achievements and Future Perspectives. <i>Molecules</i> , 2018 , 23,	4.8	29
42	Deposition of phosphorylated amyloid- β in brains of aged nonhuman primates and canines. <i>Brain Pathology</i> , 2018 , 28, 427-430	6	6
41	Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice. <i>Science Translational Medicine</i> , 2017 , 9,	17.5	259
40	The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases. <i>Immunity</i> , 2017 , 47, 566-581.e9	32.3	988
39	[F40602]: UPDATE OF THE AMYLOID HYPOTHESIS: COMPLEMENT MODULATES THE GLIAL RESPONSE TO A β PLAQUES AND MEDIATES SYNAPSE LOSS 2017 , 13, P1218		
38	Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology. <i>Current Alzheimer Research</i> , 2016 , 13, 18-29	3	147
37	Immunotherapy targeting pyroglutamate-3 A β prospects and challenges. <i>Molecular Neurodegeneration</i> , 2016 , 11, 48	19	28
36	P3-108: Beneficial Effects of Anti-Inflammatory, RNS60, in Aged APPSWE/PS1DE9 Mice 2016 , 12, P860-P860		
35	Complement and microglia mediate early synapse loss in Alzheimer mouse models. <i>Science</i> , 2016 , 352, 712-716	33.3	1400
34	The epigenetics of aging and neurodegeneration. <i>Progress in Neurobiology</i> , 2015 , 131, 21-64	10.9	247
33	Tau immunization: a cautionary tale?. <i>Neurobiology of Aging</i> , 2015 , 36, 1316-32	5.6	25
32	Complement C3-Deficient Mice Fail to Display Age-Related Hippocampal Decline. <i>Journal of Neuroscience</i> , 2015 , 35, 13029-42	6.6	208
31	An anti-pyroglutamate-3 A β vaccine reduces plaques and improves cognition in APPswe/PS1E9 mice. <i>Neurobiology of Aging</i> , 2015 , 36, 3187-3199	5.6	36
30	In Vivo Detection of Age- and Disease-Related Increases in Neuroinflammation by 18F-GE180 TSPO MicroPET Imaging in Wild-Type and Alzheimer's Transgenic Mice. <i>Journal of Neuroscience</i> , 2015 , 35, 15716-30	6.6	77
29	Anti-A β antibodies incapable of reducing cerebral A β oligomers fail to attenuate spatial reference memory deficits in J20 mice. <i>Neurobiology of Disease</i> , 2015 , 82, 372-384	7.5	31

28	Down syndrome and Alzheimer's disease: Common pathways, common goals. <i>Alzheimer's and Dementia</i> , 2015 , 11, 700-9	1.2	159
27	Immunotherapeutics for Neurological Disorders 2014 , 1215-1230		
26	P4-264: ARE ANTI-ABETA AGGREGATE-PREFERRING ANTIBODIES THE FUTURE FOR AD IMMUNOTHERAPY? 2014 , 10, P881-P882		2
25	S4-02-03: COMPLEMENT IN ALZHEIMER'S DISEASE: LESSONS FROM C3-DEFICIENT MICE 2014 , 10, P240-P240		
24	Immunotherapy for Alzheimer's disease: hoops and hurdles. <i>Molecular Neurodegeneration</i> , 2013 , 8, 36	19	134
23	Pyroglutamate-3 amyloid- β deposition in the brains of humans, non-human primates, canines, and Alzheimer disease-like transgenic mouse models. <i>American Journal of Pathology</i> , 2013 , 183, 369-81	5.8	84
22	F30102: Alzheimer's disease and Down syndrome 2013 , 9, P513-P513		
21	O20703: Complement C3-deficiency preserves hippocampal synapses and neurons with aging and improves learning and memory compared to WT mice 2013 , 9, P328-P328		
20	MER5101, a novel A β -15:DT conjugate vaccine, generates a robust anti-A β antibody response and attenuates A β pathology and cognitive deficits in APP ^{swE} /PS1 ^{E9} transgenic mice. <i>Journal of Neuroscience</i> , 2013 , 33, 7027-37	6.6	43
19	Galactic cosmic radiation leads to cognitive impairment and increased a β plaque accumulation in a mouse model of Alzheimer's disease. <i>PLoS ONE</i> , 2012 , 7, e53275	3.7	136
18	Complement component C3 and complement receptor type 3 contribute to the phagocytosis and clearance of fibrillar A β by microglia. <i>Glia</i> , 2012 , 60, 993-1003	9	108
17	Passive immunization against pyroglutamate-3 amyloid- β reduces plaque burden in Alzheimer-like transgenic mice: a pilot study. <i>Neurodegenerative Diseases</i> , 2012 , 10, 265-70	2.3	52
16	Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2011 , 3, 1	9	307
15	Can Alzheimer disease be prevented by amyloid-beta immunotherapy?. <i>Nature Reviews Neurology</i> , 2010 , 6, 108-19	15	287
14	Developing novel immunogens for a safe and effective Alzheimer's disease vaccine. <i>Progress in Brain Research</i> , 2009 , 175, 83-93	2.9	68
13	Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. <i>Nature Medicine</i> , 2008 , 14, 837-42	50.5	2779
12	Complement C3 deficiency leads to accelerated amyloid beta plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic mice. <i>Journal of Neuroscience</i> , 2008 , 28, 6333-41	6.6	229
11	A beneficial role for IL-1 beta in Alzheimer disease?. <i>Journal of Clinical Investigation</i> , 2007 , 117, 1483-5	15.9	13

10	Characterization of Abeta11-40/42 peptide deposition in Alzheimer's disease and young Down's syndrome brains: implication of N-terminally truncated Abeta species in the pathogenesis of Alzheimer's disease. <i>Acta Neuropathologica</i> , 2006 , 112, 163-74	14.3	73
9	Reduced beta-amyloid production and increased inflammatory responses in presenilin conditional knock-out mice. <i>Journal of Biological Chemistry</i> , 2004 , 279, 46907-14	5.4	120
8	Evidence for peripheral clearance of cerebral Abeta protein following chronic, active Abeta immunization in PSAPP mice. <i>Neurobiology of Disease</i> , 2003 , 14, 10-8	7.5	134
7	Intraneuronal A β 2 accumulation in Down syndrome brain. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2002 , 9, 88-102	2.7	209
6	Intranasal immunotherapy for the treatment of Alzheimer's disease: Escherichia coli LT and LT(R192G) as mucosal adjuvants. <i>Neurobiology of Aging</i> , 2002 , 23, 991-1000	5.6	63
5	Intraneuronal Abeta42 accumulation in Down syndrome brain. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2002 , 9, 88-102	2.7	100
4	Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer's disease. <i>American Journal of Pathology</i> , 2001 , 158, 1345-54	5.8	247
3	Temporal accrual of complement proteins in amyloid plaques in Down's syndrome with Alzheimer's disease. <i>American Journal of Pathology</i> , 2000 , 156, 489-99	5.8	134
2	The E280A presenilin 1 Alzheimer mutation produces increased A beta 42 deposition and severe cerebellar pathology. <i>Nature Medicine</i> , 1996 , 2, 1146-50	50.5	440
1	The Swedish mutation causes early-onset Alzheimer's disease by beta-secretase cleavage within the secretory pathway. <i>Nature Medicine</i> , 1995 , 1, 1291-6	50.5	466